Evidence map›Paper›PMID 31277311›Full record

ArticleToxins2019

A Bifunctional Adsorber Particle for the Removal of Hydrophobic Uremic Toxins from Whole Blood of Renal Failure Patients.

Marieke Sternkopf, Sven Thoröe-Boveleth, Tobias Beck, Kirsten Oleschko, Ansgar Erlenkötter, Ulrich Tschulena, Sonja Steppan, Thimoteus Speer, Claudia Goettsch, Vera Jankowski and 3 more

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Marieke SternkopfInstitute for Molecular Cardiovascular Research (IMCAR), University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.
Sven Thoröe-BovelethInstitute for Molecular Cardiovascular Research (IMCAR), University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.
Tobias BeckInstitute of Inorganic Chemistry, RWTH Aachen University, 52056 Aachen, Germany.
Kirsten OleschkoPSS Polymer Standards Service GmbH, 55120 Mainz, Germany.
Ansgar ErlenkötterFresenius Medical Care Deutschland GmbH, 66606 St. Wendel, Germany.
Ulrich TschulenaFresenius Medical Care Deutschland GmbH, 61352 Bad Homburg, Germany.
Sonja SteppanFresenius Medical Care Deutschland GmbH, 61352 Bad Homburg, Germany.
Thimoteus SpeerDepartment of Internal Medicine-Nephrology and Hypertension, Saarland University Medical Centre, 66421 Homburg/Saar, Germany.
Claudia GoettschMedical Clinic I-Cardiology, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Vera JankowskiInstitute for Molecular Cardiovascular Research (IMCAR), University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.
Joachim JankowskiInstitute for Molecular Cardiovascular Research (IMCAR), University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.
Heidi NoelsInstitute for Molecular Cardiovascular Research (IMCAR), University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany. hnoels@ukaachen.de.ORCID 0000-0003-3053-6984
European Uremic Toxin Work Group-EUToxEuropean Uremic Toxin Work Group-EUTox, Danube University Krems, 3500 Krems, Austria.
Universitätsklinikum Aachen · DEFresenius Medical Care (Germany) · DERWTH Aachen University · DEMaastricht University · NLPolymer Standards Service (Germany) · DESaarland University · DEUniversität für Weiterbildung Krems · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrophobic uremic toxins accumulate in patients with chronic kidney disease, contributing to a highly increased cardiovascular risk. The clearance of these uremic toxins using current hemodialysis techniques is limited due to their hydrophobicity and their high binding affinity to plasma proteins. Adsorber techniques may be an appropriate alternative to increase hydrophobic uremic toxin removal. We developed an extracorporeal, whole-blood bifunctional adsorber particle consisting of a porous, activated charcoal core with a hydrophilic polyvinylpyrrolidone surface coating. The adsorption capacity was quantified using analytical chromatography after perfusion of the particles with an albumin solution or blood, each containing mixtures of hydrophobic uremic toxins. A time-dependent increase in hydrophobic uremic toxin adsorption was depicted and all toxins showed a high binding affinity to the adsorber particles. Further, the particle showed a sufficient hemocompatibility without significant effects on complement component 5a, thrombin-antithrombin III complex, or thrombocyte concentration in blood in vitro, although leukocyte counts were slightly reduced. In conclusion, the bifunctional adsorber particle with cross-linked polyvinylpyrrolidone coating showed a high adsorption capacity without adverse effects on hemocompatibility in vitro. Thus, it may be an interesting candidate for further in vivo studies with the aim to increase the efficiency of conventional dialysis techniques.

Indexed as

UremiaAdsorptionBlood Cell CountCharcoalCresolsHumansIndicanPhenylacetatesPovidoneRenal DialysisRenal InsufficiencySulfuric Acid Esters4-cresol sulfateCharcoalCresolsIndicanPhenylacetatesphenylacetic acidPovidoneSulfuric Acid Estersactivated charcoaladsorptionchronic kidney diseasehemocompatibilityhemodialysisuremic toxins

Identifiers

PMID31277311
PMCPMC6669679
OpenAlexW2955715046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.